|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/29/21 Nymox Pharmaceutical Corp. 20-F 12/31/20 103:4.4M Pubco Reporting … Inc/FA |
Document/Exhibit Description Pages Size
1: 20-F Annual or Annual-Transition Report by a Foreign HTML 684K
Non-Canadian Issuer
4: EX-13.A Annual or Quarterly Report to Security Holders HTML 24K
5: EX-13.B Annual or Quarterly Report to Security Holders HTML 24K
2: EX-12.A Statement re: the Computation of Ratios HTML 28K
3: EX-12.B Statement re: the Computation of Ratios HTML 28K
12: R1 Cover HTML 59K
13: R2 Consolidated Statements of Comprehensive Loss HTML 72K
14: R3 Consolidated Statements of Financial Position HTML 83K
15: R4 Consolidated Statements of Financial Position HTML 26K
(Parenthetical)
16: R5 Consolidated Statements of Cash Flow HTML 85K
17: R6 Consolidated Statements of Changes in Equity HTML 59K
18: R7 Business Activities and Basis of Presentation HTML 30K
19: R8 Going Concern Considerations HTML 26K
20: R9 Significant Estimates HTML 25K
21: R10 Significant Accounting Policies HTML 63K
22: R11 New Accounting Standards and Interpretations HTML 28K
23: R12 Property and Equipment HTML 63K
24: R13 Intangible Assets HTML 25K
25: R14 Accounts Payable and Accrued Liabilities HTML 32K
26: R15 Operating Leases and Commitments HTML 42K
27: R16 Share Capital HTML 33K
28: R17 Stock Options HTML 47K
29: R18 Share Based Compensation HTML 30K
30: R19 Warrants HTML 43K
31: R20 Income Taxes HTML 55K
32: R21 Earnings Per Share HTML 31K
33: R22 Financial Instruments Fair Value Disclosures HTML 25K
34: R23 Finance Income and Finance Costs HTML 34K
35: R24 Segment Disclosures HTML 34K
36: R25 Concentrations HTML 29K
37: R26 Related Party Transactions HTML 34K
38: R27 Research and Development Expenses HTML 33K
39: R28 Personnel Expenses HTML 31K
40: R29 Capital Disclosures and Financial Risk HTML 25K
41: R30 Foreign Exchange Risk HTML 25K
42: R31 Credit Risk HTML 25K
43: R32 Interest Rate Risk HTML 24K
44: R33 Liquidity Risk HTML 29K
45: R34 Subsequent Events HTML 25K
46: R35 Significant Accounting Policies (Policies) HTML 92K
47: R36 Significant Accounting Policies (Tables) HTML 25K
48: R37 New Accounting Standards and Interpretations HTML 27K
(Tables)
49: R38 Property and Equipment (Tables) HTML 62K
50: R39 Accounts Payable and Accrued Liabilities (Tables) HTML 30K
51: R40 Operating Leases and Commitments (Tables) HTML 39K
52: R41 Share Capital (Tables) HTML 30K
53: R42 Stock Options (Tables) HTML 45K
54: R43 Share Based Compensation (Tables) HTML 28K
55: R44 Warrants (Tables) HTML 39K
56: R45 Income Taxes (Tables) HTML 50K
57: R46 Earnings Per Share (Tables) HTML 28K
58: R47 Finance Income and Finance Costs (Tables) HTML 32K
59: R48 Segment Disclosures (Tables) HTML 32K
60: R49 Concentrations (Tables) HTML 27K
61: R50 Related Party Transactions (Tables) HTML 28K
62: R51 Research and Development Expenses (Tables) HTML 31K
63: R52 Personnel Expenses (Tables) HTML 29K
64: R53 Liquidity Risk (Tables) HTML 27K
65: R54 Significant Accounting Policies (Details) HTML 31K
66: R55 Significant Accounting Policies (Details HTML 30K
Narrative)
67: R56 Property and Equipment (Details) HTML 48K
68: R57 Property and Equipment (Details Narrative) HTML 26K
69: R58 Intangible Assets (Details Narrative) HTML 29K
70: R59 Accounts Payable and Accrued Liabilities (Details) HTML 32K
71: R60 Operating Leases and Commitments (Details) HTML 29K
72: R61 Operating Leases and Commitments (Details 1) HTML 33K
73: R62 Operating Leases and Commitment (Details HTML 37K
Narrative)
74: R63 Share Capital (Details) HTML 26K
75: R64 Share Capital (Details Narrative) HTML 35K
76: R65 Stock Options (Details) HTML 48K
77: R66 Stock Options (Details 1) HTML 42K
78: R67 Stock Options (Details Narrative) HTML 27K
79: R68 Share Based Compensation (Details) HTML 32K
80: R69 Share Based Compensation (Details Narrative) HTML 36K
81: R70 Warrants (Details) HTML 36K
82: R71 Warrants (Details Narrative) HTML 30K
83: R72 Income Taxes (Details) HTML 37K
84: R73 Income Taxes (Details 1) HTML 27K
85: R74 Income Taxes (Details 2) HTML 79K
86: R75 Income Taxes (Details Narrative) HTML 25K
87: R76 Earnings Per Share (Details) HTML 28K
88: R77 Finance Income and Finance Costs (Details) HTML 37K
89: R78 Segment Disclosures (Details) HTML 40K
90: R79 Concentrations (Details) HTML 32K
91: R80 Related Party Transactions (Details) HTML 34K
92: R81 Related Party Transactions (Details Narrative) HTML 33K
93: R82 Research and Development Expenses (Details) HTML 37K
94: R83 Personnel Expenses (Details) HTML 31K
95: R84 Personnel Expenses (Details Narrative) HTML 29K
96: R85 Capital Disclosures and Financial Risk (Details HTML 32K
Narrative)
97: R86 Foreign Exchange Risk (Details Narrative) HTML 25K
98: R87 Credit Risk (Details Narrative) HTML 29K
99: R88 Interest Rate Risk (Details Narrative) HTML 24K
100: R89 Liquidity Risk (Details) HTML 33K
102: XML IDEA XML File -- Filing Summary XML 188K
101: EXCEL IDEA Workbook of Financial Reports XLSX 106K
6: EX-101.INS XBRL Instance -- nymox-20201231 XML 1.27M
9: EX-101.CAL XBRL Calculations -- nymox-20201231_cal XML 150K
11: EX-101.DEF XBRL Definitions -- nymox-20201231_def XML 385K
8: EX-101.LAB XBRL Labels -- nymox-20201231_lab XML 773K
10: EX-101.PRE XBRL Presentations -- nymox-20201231_pre XML 662K
7: EX-101.SCH XBRL Schema -- nymox-20201231 XSD 264K
103: ZIP XBRL Zipped Folder -- 0001640334-21-000680-xbrl Zip 122K
EXHIBIT 12 (a)
CERTIFICATION
I, Paul Averback, President and CEO of Nymox Pharmaceutical Corporation, certify that:
| 1. | I have reviewed this annual report for the period ended December 31, 2020 of Nymox Pharmaceutical Corporation; |
|
| |
| 2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
|
| |
| 3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the company as of, and for, the periods presented in this report; |
|
| |
| 4. | The company’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a – 15(e) and 15d – 15(e)), and internal control over financial reporting (as defined in the Exchange Act Rules 13a–15(f) and 15d–15(f)) for the company based on the COSO 1992 framework and we have: |
|
| a) | designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
|
| ||
|
| b) | designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with international financial reporting standards; |
|
| ||
|
| c) | evaluated the effectiveness of the company’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
|
| ||
|
| d) | disclosed in this report any change in the company’s internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the company’s internal control over financial reporting; and |
| 5. | The company’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the company’s auditors and the audit committee of the company’s board of directors (or persons performing the equivalent function): |
|
| a) | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the company’s ability to record, process, summarize and report financial information; and |
|
| ||
|
| b) | Any fraud, whether or not material, that involves management or other employees who have a significant role in the company’s internal control over financial reporting. |
| Date: March 29, 2021 | ||
|
|
| |
| By: | ||
|
| ||
|
| President and Chief Executive Officer | |
|
| Nymox Pharmaceutical Corporation | |
| This ‘20-F’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 3/29/21 | |||
| For Period end: | 12/31/20 | 20-F/A | ||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/31/16 Nymox Pharmaceutical Corp. 20-F 12/31/15 8:1.2M e3 Fil… Computershare/FA 6/03/11 Nymox Pharmaceutical Corp. 20-F/A 12/31/10 7:474K e3 Fil… Computershare/FA 6/30/04 Nymox Pharmaceutical Corp. 20-F 12/31/03 7:1.1M Foley & Lardner/FA 6/27/02 Nymox Pharmaceutical Corp. 20-F 12/31/01 2:246K Foley & Lardner/FA |